报价延迟最少15分钟:2025/09/17 16:59 EDT
盘后时段
|
||||
|
52.38 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
52.38
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.45/0.81
|
|
企业价值
12.50B
|
| 资产负债 |
|
每股账面净值
13.04
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
2.76B
|
|
每股收益
12.71
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/17 16:59 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, aliquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
